Myriad Genetics’s Ascend Plan Takes The Stage as Q2 2026 Results Hit the Volatility Curve
Company: Myriad Genetics, ticker: MYGN — Earnings snapshot, EPS considerations, and the revenue forecast ahead
Executive snapshot
Myriad Genetics (MYGN) released its second-quarter 2026 results from Salt Lake City on July 30, 2026, presenting a familiar mix of scientific momentum and budgetary gravity. Revenue for the quarter came in at $190.7 million, an 11% year-over-year decline, driven by a 1% drop in test volume and a sharper 9% fall in average revenue per test. The company also noted that payer friction and changes in estimates of cash collections weighed on the bottom line. In other words, the quarter didn’t surprise the market to the upside; it leaned toward a negative earnings surprise relative to prior expectations.
CEO Sam Raha framed the quarter as a mix of progress and required mid-course corrections. The firm is pursuing efficiency and scalability through a multidimensional program dubbed Ascend, partnered with a leading professional services firm, and is actively evaluating its product portfolio to reallocate capital for shareholder value. The CFO and executive team made clear that the near-term EPS trajectory will reflect both the cash cost of expansion and the ongoing diagnostic mix shift.
Financial highlights
- Revenue: $190.7 million for Q2 2026, down ~11% year over year.
- Test volume: 379,000 in Q2 2026, relatively flat YoY; the narrative focuses on continued volume growth in specific cancer testing avenues.
- Average revenue per test (AR per test): down about 9% YoY, contributing to the revenue shortfall.
- Guidance: The company revised its full-year 2026 financial guidance in light of the softer Prenatal Health test volumes and more conservative assumptions for AR per test.
- Strategic actions: Ascend transformation underway; expansion of commercial capabilities; continued advancement of the Cancer Care Continuum portfolio (including Prolaris + AI and Precise MRD expansions).
Operational highlights
- Cancer Care Continuum: Second-quarter test volume growth of 6% YoY, signaling some offsetting momentum within core oncology testing.
- Product and portfolio updates: Prolaris + AI for prostate cancer; expansion of Precise MRD to include colorectal and renal cancers; submission of Precise MRD for breast cancer to MolDX for coverage determination.
- Cost and efficiency: Ongoing initiatives to increase efficiency, productivity, and scalability to support gross margins and leverage a higher fixed-cost base from expanded commercial activities.
- Strategic review: The company disclosed a strategic review aimed at identifying growth, profitability, and liquidity initiatives; Ascend is the flagship effort in this regard.
Guidance and outlook
Myriad framed the second-half picture as one of recalibrating expectations rather than signaling a retreat from its strategic plan. The full-year revenue forecast was revised downward to reflect the softer Prenatal Health volumes and the more conservative view on AR per test. The company also signaled a continued focus on payer engagement and revenue-cycle initiatives to improve reimbursement predictability.
On the earnings metrics side, investors will be watching how the revised revenue forecast and the ongoing efficiency program translate into the EPS trajectory. If the company can stabilize AR per test in the back half while still gaining traction in the cancer testing franchises, it could reduce the negative delta between the current EPS consensus and eventual results. In other words, the earnings surprise risk has shifted toward the second half, and the street will test whether Ascend can unlock the operating leverage implied by the company’s portfolio moves.
Implications for peers and the broader sector
The Myriad update underscores a broader theme in molecular diagnostics: growth is accruing in high-value cancer testing and AI-enabled decision support, while legacy Prenatal Health volumes can drag the overall revenue run rate. For sector peers, the signal is twofold. First, payer dynamics and revenue-cycle management remain a material driver of near-term EPS and revenue forecasts. Second, pipeline advances in AI-enabled diagnostics and MRD (minimal residual disease) testing could become differentiators that support better AR per test and, eventually, stronger EPS momentum.
The Ascend initiative resembles a market-wide trend toward operating-model modernization—firms either double down on efficiency or risk being outpaced by more nimble competitors offering integrated data analytics with their assays. If Myriad’s strategic review identifies monetizable portfolio optimizations, its peers may mimic similar portfolio pruning and cost-control measures to preserve profitability in a market where the pace of test-volume growth is uneven.
Conclusion: a crossroads for growth and discipline
Myriad’s Q2 2026 narrative is not a dramatic pivot but a measured recalibration. The company offers a path that pairs evidence-based portfolio enhancement with a disciplined expansion of go-to-market resources, all while managing payer risk and cash collections that distort the near-term EPS picture. For investors tracking MYGN, the stock’s directional bet hinges on three levers: the durability of Cancer Care Continuum growth, the pace and profitability of Precise MRD initiatives, and the ultimate effectiveness of the Ascend program in lifting operating margins without deflating the long-term growth story.
If the company can stabilize revenue per test while growing core cancer testing volumes, the EPS consensus may begin to align more closely with revised guidance. In the meantime, the market will likely test the balance sheet against the implied revenue forecast and the speed at which the new initiatives translate into tangible profitability.